Amgen's Evolocumab Study Yields Insights into Cholesterol Medication Efficiency

Amgen's Evolocumab study has provided an update on its ongoing clinical trial, offering insights into the efficiency of the cholesterol-lowering medication. The Phase 1 study compared two versions of Evolocumab, known as Drug Substance A and B, to determine their relative bioavailability.

The trial involved healthy volunteers who were randomly assigned to receive either Drug Substance A or B, which are both injectable forms of Evolocumab designed to lower LDL levels. The study aimed to evaluate the long-term efficiency of these two versions of the medication and assess whether they could be used interchangeably.

The study was submitted on April 16, 2026, with the last update filed on October 1, 2026, indicating that data cleaning and analysis are underway. While this early trial will not have a significant impact on short-term revenue, successful relative bioavailability can lead to smoother manufacturing shifts and potential cost savings.

This news may be seen as a positive development for Amgen's Evolocumab franchise, particularly in its bid to maintain market share against rivals Regeneron and Sanofi. With the study now complete, the results will provide valuable insights into the efficiency of these medications and their potential future applications.